Press Releases for Estonia
Lygg Expands Private Airplane Flights to General Business Travel in Nordic Countries
07/02/2023 — HELSINKI, Finland — (BUSINESS WIRE) As business travel resumes its pre-pandemic pace and employees push back on the hassle of commercial airlines, Lygg is redefining business travel by […]
NuScale Power and Fermi Energia Sign MOU to Explore Advanced Nuclear Application in Estonia
Agreement to explore how NuScale’s innovative technology can benefit Estonia’s carbon-free energy goals 25/08/2022 — PORTLAND, Ore. — (BUSINESS WIRE) NuScale Power (NuScale) announced today that it has signed a […]
Milrem Robotics Brings Autonomous Warfare Capabilities to the Battlefield
19/12/2017 — TALLINN, Estonia — (BUSINESS WIRE) Milrem Robotics took the first step towards providing combat units with autonomous warfare systems last week when it successfully reached and demonstrated a […]
The Climate Corporation Acquires VitalFields to Expand Digital Agriculture Innovation for European Farmers
21/11/2016 — SAN FRANCISCO & TALLINN, Estonia — (BUSINESS WIRE) Today, The Climate Corporation, a subsidiary of Monsanto Company, announced the acquisition of VitalFields, a European farm management software company […]
E Ink’s ePaper Signage Solutions Enhance the Learning Experience at the Estonian National Museum
Newly opened museum features E Ink displays that offer custom language settings, providing a personalized experience for museum-goers 18/10/2016 — BILLERICA, Mass. — (BUSINESS WIRE) E Ink® Holdings, “E Ink” […]
AHF Launches Estonian Campaign, Petition Challenging Ministry’s Ivi Normet on HIV Meds
After years of joint non-governmental organization efforts by AIDS Healthcare Foundation (AHF) and Eesti HIV-positiivsete Vorgustik, or the Estonian Network of People Living with HIV (EHPV), the Linda Clinic – a greatly needed specialized HIV treatment resource – opened its doors in June 2013 in the town of Narva.
Otsuka Receives Opinion from CHMP on Delamanid
Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a negative opinion for delamanid for the treatment of pulmonary multidrug-resistant tuberculosis (MDR-TB) in combination with an optimised background regimen (OBR) according to WHO guidelines in patients. The CHMP considered that the duration of treatment (two months) in the Phase IIb randomised controlled trial (Trial 204) was too short to establish the effectiveness of delamanid in treating tuberculosis when added to other anti-tuberculosis medicines.